Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1250.1 - Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat at msac.secretariat@health.gov.au
Original Application: Please see Application 1250
Application Number1250.1
Application NameDiagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)
Description of Medical ServiceALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Description of Medical ConditionALK-positive advanced NSCLC.
Consultation Protocol28 May 2012 – 5 July 2012
PDF Version Consultation Protocol (PDF 250 KB)
Word Version Consultation Protocol (Word 740 KB)
Final ProtocolPDF Version Final Protocol (PDF 585 KB)
Word Version Final Protocol (Word 6128 KB)
Reports-
MSAC OutcomesPublic Summary Document - November 2014 Update (PDF 273 KB)
Public Summary Document - November 2014 Update (Word 111 KB

Meetings for this Application

Meeting Type:Date:
PASC-
ESC 12 to 13 June 2014
MSAC 3 October 2014
26 to 28 November 2014

Page currency, Latest update: 16 April, 2015